Nautilus debuted its platform at the US HUPO meeting last month and is seeking additional participants for its ongoing early access program.

When asked what Moleculent’s cell-cell interaction mapping technology provides to translational researchers, CEO Olle Ericsson explained that it adds “a new layer of information,” specifically ...

Sedana Medical AB (publ) today reports that the first patient has been treated in the company's Early Access Program (EAP) in the U.S. The program is approved by the U.S. Food and Drug Administration ...

Sujal Patel, Co-Founder and CEO, highlighted the public unveiling of the Nautilus Voyager instrument at the US Human Proteome Organization Conference, calling it a "key highlight" and noting, "The ...